BioCentury-BayHelix China Healthcare Summit - Award Winners
For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. In 2025, BayHelix and BioCentury will jointly host the BioCentury-BayHelix China Healthcare Summit (Oct. 22-24 at The St. Regis Shanghai Jingan), and will present the awards in six categories: R&D Achievement of the Year; M&A Deal of the Year; Licensing Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Woman Leader of the Year.
CONGRATULATIONS TO ALL THE 2025 AWARD WINNERS
2025 AWARD WINNERS
R&D Achievements of the Year | Syneron Bio and Earendil Labs
R&D Achievement of the year, recognizing a scientific discovery in China with direct impact to drug and/or MedTech R&D or a significant achievement in pharmaceutical and/or MedTech development milestones.
Syneron Bio and Earendil Labs
Two pioneering Chinese biotech companies leveraging AI in drug R&D.
➤ Syneron Bio, founded in 2022, secured a strategic collaboration with AstraZeneca in March 2025 for $75M in upfront payments and near-term milestones to develop macrocyclic peptide therapeutics for chronic diseases.
➤ Earendil Labs, established in December 2024, entered into a worldwide exclusive licensing agreement with Sanofi in April 2025 for $125M upfront to advance bispecific antibodies for autoimmune and inflammatory bowel diseases.
These rapid advancements underscore how Chinese biotech is at the forefront of AI-driven drug discovery and development.
M&A Deal of the Year | BioNTech and Biotheus
M&A Deal of the year, recognizing a groundbreaking pharmaceutical and/or MedTech M&A or joint venture that involves a Chinese entity, either within China or cross-border.
BioNTech and Biotheus
This deal built on earlier licensing partnerships and a wave of BioNTech’s acquisitions in China’s ADC space.
It marks BioNTech’s transformation from an mRNA COVID-19 vaccine company into one with multiple, complementary oncology pipelines—while highlighting the strength of Biotheus’s innovation and the rising global influence of Chinese biotech.
Licensing Deal of the Year | 3SBio and Pfizer
Licensing Deal of the year, recognizing a transformative pharmaceutical and/or MedTech licensing, collaboration, or technology transfer agreement that involves a Chinese entity, either within China or cross-border.
3SBio and Pfizer
This transformative agreement features a record-setting $1.25B upfront payment, the largest for a single Pfizer asset licensed from China.
It highlights the growing global impact of Chinese biotech and sets a new benchmark for cross-border collaboration.
Commercial Achievement of the Year | Ascentage Pharma
Commercial Achievement of the year, recognizing a creative model that delivered superior value to patients/payers in China and commercial success.
Ascentage Pharma
Its olverembatinib achieved strong sales growth and broad hospital access, while lisaftoclax became the first Bcl-2 inhibitor approved in China for CLL/SLL, expanding treatment options and delivering real value to patients.
Company of the Year | Sino Biopharma
Company of the year, recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, MedTech and/or healthcare industry.
Sino Biopharma
Through its strategic acquisition of LaNova Medicines and ongoing investment in 37 innovative oncology candidates, Sino is strengthening China’s oncology landscape and advancing cutting-edge therapies for patients.
Woman Leader of the Year | Dr. Crystal Qin
Woman leader of the year: recognizing an outstanding female leader whose contributions have changed the landscape, reputation and ecosystem for biopharma or MedTech in China.
Dr. Crystal Qin
The Woman Leader of the Year goes to Dr. Crystal Qin, Founder and CEO of LaNova Medicines.
Under her leadership, LaNova struck a $588 million upfront licensing deal with Merck for LM-299 and was subsequently acquired by Sino Biopharmaceutical for up to $951 million, delivering strong value to investors.
Her vision and strategic guidance have propelled LaNova onto the global stage and exemplify the growing impact of female leaders in China’s biopharma industry.
2024 Winners
For a list of 2023’s winners, please visit the 2023 China Summit web page here.
2023 Winners
For a list of 2023’s winners, please visit the 2023 China Summit web page here.